Back to homepage

Cardiology and cardiovascular disease

Influence of the duration of hospital length of stay on frequency of prophylaxis and risk for venous thromboembolism among patients hospitalized for acute medical illnesses in the USA

Authors: Alpesh Amin MD, MBA, W Richey Neuman MD, MPH, Melissa Lingohr-Smith PhD, Brandy Menges PhD, Jay Lin PhD, MBA

This article evaluates whether the duration of hospital stay influences venous thromboembolism (VTE) prophylaxis patterns and VTE risk during hospitalization and post-discharge among patients hospitalized for acute illnesses in the USA.

More

Impact of lipid-lowering therapy on glycemic control and the risk for new-onset diabetes mellitus

Authors: Constantine E Kosmas MD, PhD, Delia Silverio MD, Andreas Sourlas, Frank Garcia MD, Peter D Montan MD, Eliscer Guzman MD

This review aims to present and discuss the clinical and scientific data pertaining to the impact of lipid-lowering therapy on glycemic control and the risk for new-onset diabetes mellitus.

More

The metabolic model of heart failure: the role of sodium glucose co-transporter-2 (SGLT-2) inhibition

Authors: Muhammad Saad MD, Umut Gomceli MD, Pranav Ravi MD, Andrisael G Lacoste MD, Neil Shah MD, Timothy J Vittorio MD

In the recent era, SGLT-2 inhibitors have shown success in decreasing cardiovascular mortality in the type 2 diabetes mellitus population. This article will help the reviewer to comprehend the pathophysiology of heart failure and the potential role of SGLT-2 inhibitors in the management algorithm of heart failure and its associated risk factors in type 2 diabetes mellitus.

More

Repurposing existing drugs for cardiovascular risk management: a focus on methotrexate

Authors: Arduino A Mangoni MD, PhD, FRCP, FRACP, Sara Tommasi PhD, Angelo Zinellu PhD, Salvatore Sotgia MSc, Ciriaco Carru PhD, Matteo Piga MD, Gian Luca Erre MD

This review discusses the current challenges in the management of cardiovascular disease; the available evidence on the effects of methotrexate on inflammation, blood pressure, and surrogate markers of arterial function; suggestions for future research directions; and practical considerations with the use of methotrexate in this context.

More

Primary genetic disorders affecting high density lipoprotein (HDL)

Authors: Constantine E Kosmas MD, PhD, Delia Silverio MD, Andreas Sourlas, Frank Garcia MD, Peter D Montan MD, Eliscer Guzman MD

This review aims to describe certain genetic disorders associated with either low or high plasma HDL-C and discuss their clinical features, associated risk for cardiovascular events, and treatment options.

More